DNMT3A and systemic mastocytosis: These additional mutations affect genes encoding transcription factors, signaling molecules, epigenetic regulators, or splicing factors, resulting in shorter overall survival.[13,19,20]DNMT3A mutations are present in approximately 12% of patients with SM,[19,20] suggesting a poor prognosis.